Authors: K. Slezáková 1; Z. Sninská 1; A. Bátorová 1; A. Žákovičová 2; R. Lukačková 2; Ľ. Majerová 2; J. Marcinek 3; P. Szépe 3; L. Plank 3; K. Rejlekova 4 Authors‘ workplace: Klinika hematológie a transfúziológie LFUK a UNB 1; Medirex a. s. 2; Univerzitná nemocnica Martin 3; II. onkologická klinika LF UK a NOÚ 4 Published in: Transfuze Hematol. dnes,32, 2026, No. Ahead of Print, p. 1-6. Category: Case Reports doi: https://doi.org/10.48095/cctahd202607
Chronic myeloid leukemia (CML) has become a treatable onco-hematological disease for most of our patients over the past two decades, thanks to tyrosinkinase inhibitors. Their overall survival is comparable to that of the general population and CML is the cause of death in only a small group of patients who are resistant to multiple TKIs. However, the favorable prognosis of CML patients may be negatively affected by secondary malignancy or duplicate clonal bone marrow disease, in addition to TKI resistance. We present a detailed description of clinical, cytomorphological and molecular characteristics of 3 CML patients with coexiting Ph negative myeloproliferative disorders with driver mutations. This article also provides a review of the literature on this issue.
chronic myeloid leukaemia – myelofibrosis – Splenomegaly – tyrosinkinase inhibitors – ruxolitinib
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
